Kitazato (368A) Q1 2026 earnings summary

Executive summary

• Net sales for the three months ended June 30, 2025, rose 3.6% year-over-year to ¥2,434 million, driven by strong domestic and overseas demand for infertility treatment products.

• Operating profit declined 4.2% year-over-year to ¥1,195 million, impacted by higher exhibition and certification-related expenses.

• Profit attributable to owners of parent decreased 9.3% year-over-year to ¥745 million, mainly due to listing expenses.

Financial highlights

• Gross profit increased 2.0% year-over-year to ¥1,568 million, despite a higher cost of sales ratio.

• Ordinary profit fell 11.1% year-over-year to ¥1,125 million.

• Basic earnings per share for the quarter were ¥18.64, down from ¥20.55 in the prior year.

• Total assets as of June 30, 2025, were ¥18,471 million, down ¥1,277 million from March 31, 2025, mainly due to a decrease in cash and deposits.

• Net assets decreased by ¥894 million to ¥17,355 million, reflecting dividend payments and profit for the period.

Outlook and guidance

• Full-year forecast remains unchanged: net sales of ¥10,602 million (+2.9% YoY), operating profit of ¥5,374 million (-7.1% YoY), and profit attributable to owners of parent of ¥3,498 million (-7.7% YoY).

• Annual dividend forecast is ¥41.00 per share.